HealthCare Global Enterprises Limited share price

Key numbers

Market cap

₹ 10,431 Cr

Current price

₹ 698.65

52-week high / low

₹ 805 / 513

Stock P/E

453.7

Book value

₹ 92.1

Dividend yield

0.00%

ROCE

6.7%

ROE

1.2%

Debt to equity

1.30

Sales growth (3 yrs)

14.6%

Profit growth (3 yrs)

-22.3%

1-year return

7.4%

About HealthCare Global Enterprises Limited

HealthCare Global Enterprises Limited provides medical and healthcare services in India and internationally. The company offers cancer diagnostics services, including genomics and molecular diagnostics, digital PET, preventive oncology, physical examination, laboratory tests, home health services, digital pathology, and CTC detection; treatment services, such as medical oncology and haemato-oncology, radiation and surgical oncology, molecular imaging and theranostics, chemotherapy, robotic surgery, actinium and lutetium therapy, immunotherapy, psycho-oncology, targeted drug therapy, bone marrow transplant, pediatric oncology, organ preservation and reconstructive surgery, endocrine therapy, and liver transplant; and post care services, including patient care, psychological support, nutrition, multidisciplinary rehabilitation, and genetic counselling. It also provides cancer screening, interventional radiology, MRI, nephrology, clinical trial, hormone therapy, hematology, CAR T cell, yoga therapy, bone marrow transplant, organ-specific oncology, radiation oncology, liver transplantation, radiology and imaging, clinical laboratory, day care chemotherapy center, home health care,…

Quarterly results

Consolidated figures in ₹ crores

Concall summary (2026-08-10)

AI summary of the earnings call transcript · tone: Positive · source document

Guidance & outlook

• As a result, our payor mix improved with non -institutional contribution increasing from 67% in Q1 FY'26 to 69% in Q1 FY27.
• Adjusted EBITDA increased by 20% year-on-year to INR1,339 million, with EBITDA margins improving to 19.4% from 18.2% in Q1 FY26.

Growth & demand

• The West cluster reported a growth of 9%, led by the Maharashtra region, which grew by over 14%, while growth in the Gujarat remained relatively moderate during the quarter.
• Overall growth was led by volumes, which grew 11% year-on-year and ARPP remained broadly stable du ring the quarter.

Margins & costs

• On the profitability front, reported EBITDA for the quarter stood at INR1,223 million, excluding losses from North Bangalore and one-off costs.
• The South cluster delivered another strong quarter with revenue growing approximately 16% year-on-year, supported by healthy growth in both patient volumes and realizations.

Capex & expansion

• We also strengthened our balance sheet through a successful rights issue, expanded our leadership team, successfully commissioned our North Bangalore hospital and continue to advance our brownfield expansion pipeline and other growth initiatives.
• As a reminder, the South cluster numbers include the newly commissioned North Bangalore hospital, which contributed INR67 million of revenue.

Balance sheet & cash

• As you see that the interest cost has come down during this quarter because of the proceeds that we have raised from the right issue that has been used for the purpose of repayment of some of the debt almost amounting to INR170 crore.
• We almost had an operating cash flow before the working capital changes of ~INR125 crore INR125 crore.

Peers in Medical Care Facilities

• Apollo Hospitals Enterprise Limited
• Max Healthcare Institute Limited
• Manipal Health Enterprises Limited
• Aster DM Quality Care Limited
• Fortis Healthcare Limited
• Global Health Limited
• Narayana Hrudayalaya Limited
• Krishna Institute of Medical Sciences Limited
• Rainbow Children's Medicare Limited
• Park Medi World Limited